Vontier Prepared For A Solid 2024 With Revenue And Margin Growth: Analyst

+1.69% Pre

Vontier Corporation Common Stock

VNT

0.00

BofA Securities analyst Andrew Obin upgraded Vontier Corp (NYSE:VNT) to Buy from Neutral at an increased price target of $40 (from $37).

The analyst sees more room to run for the company and forecasts all-in organic revenue growth and margin expansion in 2024 as U.S. fuel dispenser headwinds fade.

Obin expects 4% organic revenue CAGR and 170bps cumulative adjusted operating margin expansion to drive a 10% adj. EPS CAGR (FY23-FY26).

The analyst's FY24 estimates now exclude the completed Coats divestiture and despite this, their FY24E adj. EPS is higher at $3.14 (vs. $3.09 consensus) and FY25 adj. EPS is $0.16 higher at $3.51 (+12% Y/Y).

The analyst also expects contract wins for the iNFX payments platform to add to multi-year visibility and organic FCF generation (BofA FY24 $468 million) to be led by proceeds from the Coats divestiture.

Price Action: VNT shares are trading higher by 2.64% at $34.45 on the last check Thursday.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Is SelectQuote, Inc.'s (NYSE:SLQT) Stock Price Struggling As A Result Of Its Mixed Financials?

Antero Midstream (NYSE:AM) Will Pay A Dividend Of $0.225

Coeur Mining (CDE): Assessing Valuation After Upbeat Analyst Upgrades and Raised Earnings Estimates

Is Oruka Therapeutics’ (ORKA) Fundraising Spree a Sign of Strategic Flexibility or Underlying Caution?

Did Slowing Organic Sales Just Shift Allegion's (ALLE) Investment Narrative?

Alaska Air Group (ALK): Examining Valuation After Recent Share Price Pullback

Zymeworks (ZYME): Evaluating Valuation Following New Leadership and Key Regulatory Wins

Vontier Expects Its Q3 2025 Sales To Be Slightly Above The Midpoint Of Prior Guidance And Adjusted EPS To Be Near Or At The High End Of Its Forecast